Cancers, Vol. 12, Pages 1773: Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
Cancers, Vol. 12, Pages 1773: Prognostic Significance of PET/CT in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline Chemoimmunotherapy
Cancers doi: 10.3390/cancers12071773
Authors:
Marika Porrazzo
Emanuele Nicolai
Mara Riminucci
Candida Vitale
Marta Coscia
Lorenzo De Paoli
Angela Rago
Giulia Buscicchio
Giacomo Maestrini
Silvio Ligia
Alessio Di Prima
Alessandro Corsi
Roberto Caronna
Gianluca Gaidano
Francesca Romana Mauro
The role of positron emission tomography/computed tomography (PET/CT) in identifying Richter Syndrome (RS) is well established, while its impact on the survival of patients with chronic lymphocytic leukemia (CLL) has been less explored. The clinical characteristics and PET/CT data of 40 patients with a biopsy-proven CLL who required frontline chemoimmunotherapy, FCR (fludarabine, cyclophosphamide, rituximab) in 20 patients, BR (bendamustine, rituximab) in 20, were retrospectively analyzed. Standardized uptake volume (SUVmax) values ≥ 5 were observed more frequently in patients with deletion 11q (p = 0.006) and biopsies characterized by a rate of Ki67 positive cells ≥ 30% (p = 0.02). In the multivariate analysis, the presence of large and confluent PCs emerged as the only factor with a negative impact on progression-free survival (PFS), and overall survival (OS). Deletion 11q also revealed a significant and independent effect on PFS. SUVmax values ≥ 5 showed no statisti...
Source: Cancers - Category: Cancer & Oncology Authors: Marika Porrazzo Emanuele Nicolai Mara Riminucci Candida Vitale Marta Coscia Lorenzo De Paoli Angela Rago Giulia Buscicchio Giacomo Maestrini Silvio Ligia Alessio Di Prima Alessandro Corsi Roberto Caronna Gianluca Gaidano Francesca Romana Mauro Tags: Article Source Type: research
More News: Cancer | Cancer & Oncology | Candida | Chronic Leukemia | Chronic Lymphocytic Leukemia | CT Scan | Leukemia | PET Scan | Rituxan | Statistics | Treanda